Understanding Suboptimal Response to Immune Checkpoint Inhibitors

• DOI: 10.1002/adbi.202101319
• Publication Date: 2022-03-28T03:19:25Z
• Authors: Mojun Zhu; Henan Zhang; Katrina S. Pedersen; Nathan R. Foster; Brandy L. Jaszewski; Xin Liu; Jacob B. Hirdler; Zesheng An; Tanios S. Bekaii‐...; Thorvardur R. Hal...; Patrick M. Boland; Yiyi Yan; Joleen H. Hubbard; Wen Wee Ma; Harry H. Yoon; Alexander Revzin; Martin E. Fernand...; Michael J. Overman; Robert R. McWilliams; Haidong Dong
• Keywords: Immune checkpoint

Abstract Immune checkpoint inhibitors (ICIs), as a novel class of anticancer therapy, can be more efficacious and less toxic than chemotherapy, but their clinical success is confined to certain tumor types. Elucidating targets, mechanisms scope action, potential synergism with chemotherapy and/or targeted therapies are critical widen indications. Treatment response an ICI targeting programmed death‐1 (anti‐PD‐1) sought understood here by conducting preplanned correlative analysis phase II trial in patients small bowel adenocarcinoma (SBA). The cytolytic capacity circulating immune cells cancer using ex vivo cytotoxicity assay evaluated, the utility biomarkers investigated predict monitor treatment effect anti‐PD‐1. Baseline expression Bim NKG7 upregulation CX3CR1 T associated benefit anti‐PD‐1 SBA. Overall, these findings suggest that frequency circulating, effector may differentiate ICIs, providing strong rationale support monitoring patient peripheral blood.